Saturday 17 October 2026
Export GNPX’s income statement to Excel — free account
GENPREX
GNPX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 95.0% and free cash flow fell 33.0%, each against the same quarter a year earlier.
2.11
0.18
−7.86%
Follow GNPX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.67 | 3.84 | 5.61 | 6.76 |
Net Debt/EBITDA |
0.33 | 2.23 | 4.02 | 3.38 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 1.08 | 0.70 | 1.16 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(92.12) | (96.43) | (9.92) | (10.86) | |
Cash per Share |
31.89 | 184.26 | 57.06 | 32.04 | |
Shareholders Equity per Share |
22.19 | 187.34 | 53.53 | 31.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.19 | 187.34 | 53.53 | 31.28 | |
Free Cash Flow |
(3.19) | (4.10) | (3.14) | (5.14) | |
Working Capital |
(0.84) | 6.18 | 15.45 | 13.50 | |
Net Current Asset Value |
(1.08) | 6.16 | 15.43 | 13.50 | |
| Other line items | |||||
Quick Ratio |
0.43 | 3.60 | 5.38 | 6.47 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(92.12) | (96.43) | (9.92) | (10.86) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.46 | 0.91 | 1.59 | 0.61 | |
Average Assets |
3.73 | 7.14 | 13.16 | 10.48 | |
Average Common Equity |
1.22 | 4.79 | 10.40 | 8.09 |
Columns are period end dates